Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-05-05 Director's Dealing
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Mandatory notification of trade
Director's Dealing Classification · 98% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsidere») og deres nærstående' (Form for notification of transactions executed by persons discharging managerial responsibilities ('insiders') and their connected persons). This structure, detailing transactions (Kjøp/Buy) by insiders (HENRIK JAKOBSEN) and related parties, is characteristic of mandatory regulatory filings concerning insider trading or director's dealings. Comparing this to the definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate fit, as it specifically covers 'Report of personal share transactions by company directors and executives (insider trades)'. The document is a detailed report of the transaction, not just an announcement of a report (RPA/RNS).
2023-05-05 Norwegian
Mandatory notification of trade
Director's Dealing Classification · 99% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsider») og deres nærstående' (Form for reporting transactions carried out by persons discharging managerial responsibilities ('insiders') and their connected persons). It details a 'Salg' (Sale) transaction involving shares (Aksje) by an insider (HENRIK JAKOBSEN) and reports specific details like ISIN, price (47,5 NOK), volume (13,800), and date (05.05.2023). This structure and content are characteristic of mandatory insider trading disclosures, which fall under the category of Director's Dealing reports in many jurisdictions. Based on the provided definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification for reports of personal share transactions by company directors and executives.
2023-05-05 Norwegian
Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled "Mandatory notification of trade" and details transactions involving shares of Gentian Diagnostics ASA completed by a close associate of a primary insider (Holta Invest AS). It explicitly mentions compliance with EU Market Abuse Regulation and Norwegian Securities Trading Act, which are standard requirements for insider trading disclosures. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors or their associates). The filing type code DIRS (Director's Dealing) is the most appropriate classification.
2023-05-05 English
First quarter 2023 report
Investor Presentation Classification · 98% confidence The document is explicitly titled 'Q1 23 Presentation' and contains slides detailing product pipelines, market analysis, financial highlights for '1Q23' (First Quarter 2023), sales figures, and progress updates. This structure is characteristic of an Investor Presentation (IP) used to communicate quarterly performance and strategy to investors, rather than a full regulatory report (like 10-K or IR) or a simple announcement of a report (RPA). The content focuses on strategy, product development (GCAL, NT-proBNP), and financial review for the quarter.
2023-05-05 English
First quarter 2023 report
Investor Presentation Classification · 99% confidence The document text explicitly details 'First quarter 2023 highlights', provides operational summaries for '1Q23', discusses sales figures, EBITDA, R&D costs for the quarter, and outlines product development progress during the quarter. This structure—a comprehensive review of a specific, shorter reporting period (three months) including financial metrics and operational updates—is characteristic of an Interim/Quarterly Report. It is more detailed than a simple Earnings Release (ER) but is not the full Annual Report (10-K). Therefore, the classification is Interim / Quarterly Report (IR).
2023-05-05 English
First quarter 2023 report
Earnings Release Classification · 100% confidence The document explicitly states it is the "First quarter 2023 report" and proceeds to announce key financial highlights (record sales, EBITDA, R&D costs) for that period. This content structure—announcing key figures for a specific interim period—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR) nor is it merely an announcement of a report's publication (RPA). The document is short and focuses on results, fitting the definition of an Earnings Release. Q1 2023
2023-05-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.